Method and system for optimized scheduling of workflows
    1.
    发明授权
    Method and system for optimized scheduling of workflows 有权
    优化工作流程调度的方法和系统

    公开(公告)号:US08583467B1

    公开(公告)日:2013-11-12

    申请号:US13592869

    申请日:2012-08-23

    IPC分类号: G06Q10/00

    摘要: A computer-implemented method is provided for optimizing scheduling and resource allocation for a workflow. The method includes receiving i) resource information representing resources available for allocation to the workflow and ii) one or more workflow constraints. The method determines one or more probable sequences for executing the workflow. Each probable sequence includes tasks usable to execute at least a portion of the workflow. Each task is assigned a probability of task execution. The method assigns a probability of sequence execution to each of the probable sequences based on the probability of task execution of the tasks forming the probable sequence. The method further determines an optimized scenario for scheduling the workflow based on the probable sequences. The optimized scenario can have an optimized probability of completion.

    摘要翻译: 提供了一种用于优化工作流的调度和资源分配的计算机实现的方法。 该方法包括:i)表示可用于分配给工作流的资源的资源信息,以及ii)一个或多个工作流约束。 该方法确定用于执行工作流的一个或多个可能的序列。 每个可能的序列包括可用于执行工作流的至少一部分的任务。 每个任务被赋予任务执行的概率。 该方法基于任务执行形成可能序列的任务的概率,将每个可能序列的序列执行概率分配。 该方法还基于可能的序列确定用于调度工作流的优化场景。 优化的情景可以具有优化的完成概率。

    Heterocycle-coupled substituted pyrrolo[3,2-c]pyridin-2-carboxylic acids
    3.
    发明授权
    Heterocycle-coupled substituted pyrrolo[3,2-c]pyridin-2-carboxylic acids 失效
    杂环偶联取代的吡咯并[3,2-c]吡啶-2-羧酸

    公开(公告)号:US5468750A

    公开(公告)日:1995-11-21

    申请号:US273943

    申请日:1994-07-12

    摘要: A compound of formula ##STR1## in which A represents S;R.sub.1 is selected from the group consisting of OH, (C.sub.1 -C.sub.12)alkyl, (C.sub.1 -C.sub.12)alkoxy, benzyloxy, phenyl, benzyl (C.sub.1 -C.sub.4)alkyl NZ.sub.1 Z.sub.2, and NZ.sub.1 Z.sub.2 ;R.sub.2 is selected from the group consisting of OH, SH, (C.sub.1 -C.sub.4)alkoxy, (C.sub.1 -C.sub.4)alkylthio, and NZ.sub.1 Z.sub.2 ;R.sub.3 is selected from the group consisting of H, (C.sub.1 -C.sub.4)alkyl, (C.sub.1 -C.sub.4)alkylthio, (C.sub.1 -C.sub.4)alkoxy, phenyl, and benzyl;B is selected from the group consisting of phenyl; pyridyl; phenyl substituted by one or more groups selected from halo, (C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.6)alkoxy, CF.sub.3, CH.sub.2 NZ.sub.1 Z.sub.2, and NZ.sub.1 Z.sub.2 wherein Z.sub.1 and Z.sub.2 are selected, independently of each other, from the group consisting of H, (C.sub.1 -C.sub.6)alkyl, formyl, and benzyl or --NZ.sub.1 Z.sub.2 is selected from the group consisting of pyrrolidinyl, piperidinyl, morpholino, hexahydroazepino, ##STR2## piperazino, piperazino substituted in position 4 by (C.sub.1 -C.sub.8)alkyl, benzyl or diphenylmethyl; and pyridyl substituted by one or more groups selected from halo, (C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.6)alkoxy, CF.sub.3, CH.sub.2 NZ.sub.1 Z.sub.2, and NZ.sub.1 Z.sub.2 wherein Z.sub.1 and Z.sub.2 are selected, independently of each other, from the group consisting of H, (C.sub.1 -C.sub.6)alkyl, formyl, and benzyl, or NZ.sub.1 Z.sub.2 is selected from the group consisting of pyrrolidinyl, piperidinyl, morpholino, hyxahydroazepino, ##STR3## piperazino, and piperazino substituted in position 4 by (C.sub.1 -C.sub.8)alkyl, benzyl or diphenylmethyl; or its salt with an acid or a base.

    摘要翻译: 其中A表示S的式(Ⅰ)化合物; R1选自OH,(C1-C12)烷基,(C1-C12)烷氧基,苄氧基,苯基,苄基(C1-C4)烷基NZ1Z2和NZ1Z2; R2选自OH,SH,(C1-C4)烷氧基,(C1-C4)烷硫基和NZ1Z2; R 3选自H,(C 1 -C 4)烷基,(C 1 -C 4)烷硫基,(C 1 -C 4)烷氧基,苯基和苄基; B选自苯基; 吡啶基 被选自卤素,(C1-C6)烷基,(C1-C6)烷氧基,CF3,CH2NZ1Z2和NZ1Z2中的一个或多个基团取代的苯基,其中Z1和Z2彼此独立地选自H, (C 1 -C 6)烷基,甲酰基和苄基或-NZ 1 Z 2选自吡咯烷基,哌啶基,吗啉代,六氢氮杂环庚烷,哌嗪子基,哌嗪基,其在第4位被(C 1 -C 8)烷基取代,苄基或二苯基甲基 ; 和被一个或多个选自卤素,(C 1 -C 6)烷基,(C 1 -C 6)烷氧基,CF 3,CH 2 NZ 1 Z 2和NZ 1 Z 2的基团取代的吡啶基,其中Z 1和Z 2彼此独立地选自H ,(C 1 -C 6)烷基,甲酰基和苄基,或NZ 1 Z 2选自吡咯烷基,哌啶基,吗啉代,杂环吖庚因,哌嗪子基和在位置4上被(C 1 -C 8)烷基取代的哌嗪基,苄基 或二苯基甲基; 或其与酸或碱的盐。

    Substituted thienyl- or pyrrolylcarboxyclic acid derivatives, their
preparation and medicines containing them
    4.
    发明授权
    Substituted thienyl- or pyrrolylcarboxyclic acid derivatives, their preparation and medicines containing them 失效
    取代的噻吩基或吡咯基羧基酸衍生物,其制备方法和含有它们的药物

    公开(公告)号:US5360799A

    公开(公告)日:1994-11-01

    申请号:US109073

    申请日:1993-08-19

    摘要: Compounds of formula ##STR1## in which R.sub.1 represents OH, (C.sub.1 -C.sub.12)alkyl, (C.sub.1 -C.sub.12)alkoxy, benzyloxy, benzyl, phenyl, (C.sub.1 -C.sub.4)alkylNZ.sub.1 Z.sub.2 or NZ.sub.1 Z.sub.2 ; R.sub.2 represents OH, SH, (C.sub.1 -C.sub.4)alkoxy, (C.sub.1 -C.sub.4)alkylthio or NZ.sub.1 Z.sub.2 ; R.sub.3 represents H, (C.sub.1 -C.sub.4)alkyl, (C.sub.1 -C.sub.4)alkylthio, (C.sub.1 -C.sub.4)alkoxy, phenyl or benzyl; A represents N and R represents H or (C.sub.1 -C.sub.4)alkyl which can be substituted by phenyl or NZ.sub.1 Z.sub.2 ; B represents phenyl which is coupled to the pyridyl ring and is optionally substituted by one or more groups chosen from halo, (C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.6)alkoxy, CF.sub.3, CH.sub.2 NZ.sub.1 Z.sub.2 or NZ.sub.1 Z.sub.2 ; and Z.sub.1 and Z.sub.2 represent, independently of each other, H, (C.sub.1 -C.sub.6) alkyl, formyl or benzyl, or they form with the nitrogen atom to which they are attached an optionally substituted saturated heterocycle and their salts.

    摘要翻译: 其中R 1表示OH,(C 1 -C 12)烷基,(C 1 -C 12)烷氧基,苄氧基,苄基,苯基,(C 1 -C 4)烷基NZ 1 Z 2或NZ 1 Z 2的式I化合物; R2代表OH,SH,(C1-C4)烷氧基,(C1-C4)烷硫基或NZ1Z2; R3表示H,(C1-C4)烷基,(C1-C4)烷硫基,(C1-C4)烷氧基,苯基或苄基; A表示N,R表示H或可被苯基或NZ1Z2取代的(C1-C4)烷基; B表示与吡啶基环偶联并且任选被一个或多个选自卤素,(C 1 -C 6)烷基,(C 1 -C 6)烷氧基,CF 3,CH 2 NZ 1 Z 2或NZ 1 Z 2的基团取代的苯基; 并且Z 1和Z 2彼此独立地表示H,(C 1 -C 6)烷基,甲酰基或苄基,或者与它们所连接的氮原子一起形成任选取代的饱和杂环及其盐。